ClinicalTrials.gov
public full text
Public Domain
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
breast-cancercolorectal-cancerendometrial-canceresophageal-cancerhead-and-neck-cancernon-small-cell-lung-cancerovarian-cancerpancreatic-cancer
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of DM5167 in Patients With Advanced Solid Tumors#1093553
- Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.#1033641
- A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors#1127638
- GH21 Combined With D-1553 in KRAS G12C Mutant Advanced Solid Tumors#1094222
- A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors#862657
Record · ID 1045159
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive